Cargando…
1563MO CoVigi phase IV multicentric trial evaluating COVID-19 vaccination adverse events and immune response dynamics in cancer patients: First results on antibody and cellular immunity
Autores principales: | Obermannova, R., Demlova, R., Selingerova, I., Doubek, M., Okrouhlicova, D., Mlnarikova, M., Pilatova, K., Nevrlka, J., Lejdarova, H., Weinbergerova, B., Cermakova, Z., Valik, D., Mayer, J., Kiss, I., Zdrazilova-Dubska, L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Society for Medical Oncology. Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454423/ http://dx.doi.org/10.1016/j.annonc.2021.08.1556 |
Ejemplares similares
-
Assessment of Immune Response Following Dendritic Cell-Based Immunotherapy in Pediatric Patients With Relapsing Sarcoma
por: Fedorova, Lenka, et al.
Publicado: (2019) -
Circulating T cell subsets are associated with clinical outcome of anti-VEGF-based 1st-line treatment of metastatic colorectal cancer patients: a prospective study with focus on primary tumor sidedness
por: Bencsikova, Beatrix, et al.
Publicado: (2019) -
Editorial: Precision/Personalized Pediatric Oncology and Immune Therapies: Rather Customize Than Randomize
por: Kýr, Michal, et al.
Publicado: (2020) -
Role of platelet chemokines, PF-4 and CTAP-III, in cancer biology
por: Pilatova, Katerina, et al.
Publicado: (2013) -
B-Cell Activating Factor as a Cancer Biomarker and Its Implications in Cancer-Related Cachexia
por: Rihacek, Michal, et al.
Publicado: (2015)